| Retisert (fluocinolone acetonide intravitreal implant) / Bausch Health, EyePoint Pharma |
NCT00570830: Retisert and Cataract Surgery in Patients With Severe Uveitis |
|
|
| Completed | N/A | 21 | US | Retisert (fluocinolone acetonide implant), 1 | Duke University | Intermediate Uveitis, Posterior Uveitis | 11/07 | 05/08 | | |
NCT00952614: A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion |
|
|
| Completed | N/A | 29 | US | fluocinolone acetonide (Retisert Implant, Bausch and Lomb), Retisert Implant, Bausch and Lomb, Rochester, NY | Glenn Jaffe, Bausch & Lomb Incorporated | Central Retinal Vein Occlusion | 05/09 | 05/09 | | |
NCT03145025: Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant |
|
|
| Completed | N/A | 3 | US | Retisert, Fluocinolone Acetonide Intravitreal Implant | Bausch & Lomb Incorporated | Uveitis, Posterior | 09/18 | 03/19 | | |
NCT01060787: Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant |
|
|
| Completed | N/A | 98 | US | Fluocinolone Acetonide 0.59 mg, Retisert, Fluocinolone Acetonide 2.1 mg | Bausch & Lomb Incorporated | Inflammation, Uveitis | 03/19 | 06/19 | | |
